ArticleMolecular therapy : the journal of the American Society of Gene Therapy2018
Personalized Cancer Vaccine Platform for Clinically Relevant Oncolytic Enveloped Viruses.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 49 citations in OpenAlex.
- Strategic Advances in Targeted Delivery Carriers for Therapeutic Cancer Vaccines.International journal of molecular sciences · 2025Review
- Personalizing Oncolytic Immunovirotherapy Approaches.Molecular diagnosis & therapy · 2024Article
- Exploring the DNAHeliyon · 2024Article
- Immunopeptidomics in the cancer immunotherapy era.Exploration of targeted anti-tumor therapy · 2024Review
- Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.Journal for immunotherapy of cancer · 2023Article
- Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions.Journal of nanobiotechnology · 2023Review
- Biomimetic and bioinspired nano-platforms for cancer vaccine development.Exploration (Beijing, China) · 2023Review
- In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer.Vaccine · 2023Article
- Systems Biology Approaches for the Improvement of Oncolytic Virus-Based Immunotherapies.Cancers · 2023Review
- Systemic delivery of glycosylated-PEG-masked oncolytic virus enhances targeting of antitumor immuno-virotherapy and modulates T and NK cell infiltration.Theranostics · 2023Article
- A novel cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubella.Molecular therapy oncolytics · 2022Article
- Cancer gene therapy goes viral: viral vector platforms come of age.Radiology and oncology · 2022Article
- An Inter-Supplementary Biohybrid System Based on Natural Killer Cells for the Combinational Immunotherapy and Virotherapy of Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Novel personalized cancer vaccine platform based on Bacillus Calmette-Guèrin.Journal for immunotherapy of cancer · 2021Article
- Oncolytic Adenoviruses for Cancer Therapy.International journal of molecular sciences · 2021Review
- Viral Nanoparticles: Cancer Vaccines and Immune Modulators.Advances in experimental medicine and biology · 2021Article
- Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.Frontiers in immunology · 2020Review
- Metabolic Traits in Cutaneous Melanoma.Frontiers in oncology · 2020Review
- Enhancing the Efficacy of Tumor Vaccines Based on Immune Evasion Mechanisms.Frontiers in oncology · 2020Review
- Artificially cloaked viral nanovaccine for cancer immunotherapy.Nature communications · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
Abstract
The approval of the first oncolytic virus for the treatment of metastatic melanoma and the compiling evidence that the use of oncolytic viruses can enhance cancer immunotherapies targeted against various immune checkpoint proteins has attracted great interest in the field of cancer virotherapy. We have developed a novel platform for clinically relevant enveloped viruses that can direct the virus-induced immune response against tumor antigens. By physically attaching tumor-specific peptides onto the viral envelope of vaccinia virus and herpes simplex virus 1 (HSV-1), we were able to induce a strong T cell-specific immune response toward these tumor antigens. These therapeutic peptides could be attached onto the viral envelope by using a cell-penetrating peptide sequence derived from human immunodeficiency virus Tat N-terminally fused to the tumor-specific peptides or, alternatively, therapeutic peptides could be conjugated with cholesterol for the attachment of the peptides onto the viral envelope. We used two mouse models of melanoma termed B16.OVA and B16-F10 for testing the efficacy of OVA SIINFEKL-peptide-coated viruses and gp100-Trp2-peptide-coated viruses, respectively, and show that by coating the viral envelope with therapeutic peptides, the anti-tumor immunity and the number of tumor-specific CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.